XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer

Documenti analoghi

• Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort
  di: Min Xiong, et al.
  Pubblicazione: (2024)
• LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer
  di: Qi Zhang, et al.
  Pubblicazione: (2025)
• p95HER2 expression in HER2‐positive breast cancer with primary resistance
  di: Chih Wan Goh, et al.
  Pubblicazione: (2024)
• Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study
  di: Thiti Susiriwatananont, et al.
  Pubblicazione: (2025)
• Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK‐4/6 Inhibitors Therapy
  di: Nilufer Bulut, et al.
  Pubblicazione: (2026)